These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10971177)

  • 1. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Mizumoto T; Hamamoto R
    Oncology; 2000 Aug; 59(2):166-73. PubMed ID: 10971177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
    Yamashita J; Hideshima T; Shirakusa T; Ogawa M
    Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer.
    Nishimura R; Nagao K; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Higuchi A; Ikeda K
    Eur J Cancer; 1997 Aug; 33(9):1407-12. PubMed ID: 9337682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer.
    Koyama H; Tominaga T; Asaishi K; Abe R; Iino Y; Enomoto K; Miura S; Nomura Y; Nakazato H; Abe O
    Oncology; 1999; 56(4):283-90. PubMed ID: 10343191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
    Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
    Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect.
    Kurebayashi J; Yamamoto S; Otsuki T; Sonoo H
    Br J Cancer; 1999 Feb; 79(3-4):631-6. PubMed ID: 10027341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care.
    Kurihara T; Higashi Y; Suemasu K; Tabei T; Ishiguro S; Iino Y; Morishita Y; Takeda F
    Surg Today; 1998; 28(9):979-84. PubMed ID: 9744415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
    Murray A; Clinton O; Earl H; Price M; Moore A
    Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
    Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
    Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medroxyprogesterone Acetate as Part of Palliative Care for Terminal-Stage Breast Cancer Patients--A Report of Two Cases].
    Okamoto A; Ueno H; Yamashiro A; Okada M; Nakasone A; Hatano T; Harada A; Taniguchi A; Onishi K; Kwon C; Fukazawa K; Taguchi T; Amaya F; Hosokawa T
    Gan To Kagaku Ryoho; 2016 Mar; 43(3):345-8. PubMed ID: 27067852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
    Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
    J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
    Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
    Abe O; Asaishi K; Izuo M; Enomoto K; Koyama H; Tominaga T; Nomura Y; Ohshima A; Aoki N; Tsukada T
    Surg Today; 1995; 25(8):701-10. PubMed ID: 8520164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
    Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
    J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women.
    Ohtsu T; Fujii H; Wakita H; Igarashi T; Itoh K; Imoto S; Kohagura M; Sasaki Y
    Cancer Chemother Pharmacol; 1998; 42(1):1-8. PubMed ID: 9619751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer.
    Xiangying M; Shikai W; Zefei J; Bing S; Yan M; Xin Z; Lijuan D; Yue W; Tao W; Shaohua Z; Santai S
    Swiss Med Wkly; 2013; 143():w13765. PubMed ID: 23740185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
    Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.